Foselutoclax

A BCL-2 inhibitor used in cancer treatment

Foselutoclax
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Foselutoclax is a small molecule BCL-2 inhibitor that is being investigated for its potential use in the treatment of various types of cancer. It is designed to induce apoptosis in cancer cells by inhibiting the B-cell lymphoma 2 (BCL-2) protein, which is often overexpressed in cancer cells and contributes to their survival.

Mechanism of Action

Foselutoclax functions by targeting the BCL-2 protein, a key regulator of the apoptosis pathway. BCL-2 is an anti-apoptotic protein that prevents the activation of the apoptotic process, allowing cancer cells to evade programmed cell death. By inhibiting BCL-2, foselutoclax promotes the release of pro-apoptotic factors, leading to the activation of the caspase cascade and subsequent cell death.

Clinical Development

Foselutoclax is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various hematological malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Early-phase trials have shown promising results, with some patients experiencing significant reductions in tumor burden.

Pharmacokinetics

The pharmacokinetic profile of foselutoclax is characterized by its absorption, distribution, metabolism, and excretion properties. It is administered orally and has been shown to have a favorable bioavailability. The drug is metabolized primarily in the liver and excreted through the kidneys.

Side Effects

Common side effects of foselutoclax include nausea, fatigue, and diarrhea. More serious adverse effects can include neutropenia, thrombocytopenia, and tumor lysis syndrome, which require careful monitoring and management during treatment.

Research and Future Directions

Ongoing research is focused on optimizing the dosing regimen of foselutoclax and exploring its use in combination with other anticancer agents. Studies are also investigating its potential application in solid tumors, expanding its therapeutic scope beyond hematological cancers.

Related Pages

• BCL-2 family
• Apoptosis
• Chronic lymphocytic leukemia
• Non-Hodgkin lymphoma